Companies › Heron Therapeutics
2 active drug programs in 5 registered trials: 4 Phase 4, 1 Phase 3; Other, Genitourinary.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Granisetron Serotonin 3a (5-HT3a) receptor antagonist | HTR3A | Phase 4 | Chemotherapy-Induced Nausea and Vomiting (CINV); TMD; Nausea With Vomiting Chemotherapy-Induced; Nephrotoxicity | – |
| HTX-011 Fixed-ratio combination of bupivacaine and meloxicam; bupivacaine is a local anesthetic th | TRPV1 | Phase 4 | Analgesia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05109312 | HTX-011 | Phase 4 | Analgesia | Other | Jun 2024 |
| NCT05434663 | Granisetron | Phase 4 | Chemotherapy-Induced Nausea and Vomiting (CINV) | Other | Oct 2025 |
| NCT07401745 | Granisetron | Phase 4 | TMD | Other | Jul 2026 |
| NCT04150614 | Granisetron | Phase 4 | Nausea With Vomiting Chemotherapy-Induced | Other | Mar 2027 |
| NCT03817970 | Granisetron | Phase 3 | Nephrotoxicity | Genitourinary | Sep 2027 |
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Endo USA Inc., a Keenova Therapeutics Company Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.